睿知中国医院研究地图
候选清单

南昌

江西省肿瘤医院

Jiangxi Cancer Hospital

在本站收录的 53 种疾病中,这家医院列在其中 6 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

江西省肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma14 篇牵头论文牵头 7 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma2 篇牵头论文牵头 1 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma8 篇牵头论文
  4. 胃癌Stomach cancer4 篇牵头论文
  5. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  6. 骨肉瘤Osteosarcoma3 篇牵头论文

未列出的收录疾病:肝母细胞瘤、脊索瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.6%。

牵头论文
14
2021–2025 年
牵头试验
16
任何状态,ClinicalTrials.gov
牵头的开放试验
7
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 3320232024: 2220242025: 772025

南昌有 3 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 12

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:
    分期
    III期
    开始
    2026-04
    登记号
    NCT07559877

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:江西省肿瘤医院南昌

  2. 正在招募
    Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
    分期
    III期
    开始
    2025-01
    登记号
    NCT06752239

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:江西省肿瘤医院南昌

  3. 正在招募
    Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2025-01
    登记号
    NCT07085988

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江西省肿瘤医院南昌

  4. 正在招募
    Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
    分期
    II期
    开始
    2025-10
    登记号
    NCT07277764

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:江西省肿瘤医院南昌

  5. 正在招募
    The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
    分期
    未注明
    开始
    2024-01
    登记号
    NCT06182657

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江西省肿瘤医院南昌

  6. 正在招募
    Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2024-03
    登记号
    NCT06277050

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:江西省肿瘤医院;另有 2 家列出的医院为研究中心南昌、赣州

  7. 邀请入组
    Prognostic Value of TIL in Nasopharyngeal Carcinoma
    分期
    未注明
    开始
    2025-01
    登记号
    NCT06763640

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:江西省肿瘤医院南昌

  8. 正在招募
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    分期
    I/II期
    开始
    2025-11
    登记号
    NCT07258979

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、东莞、南宁、南昌、厦门、广州、成都、昆明、杭州、桂林、江门、海口、福州、重庆、长沙、韶关

  9. 正在招募
    IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
    分期
    III期
    开始
    2024-01
    登记号
    NCT05941741

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 2 家列出的医院为研究中心南宁、南昌、广州

  10. 正在招募
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    分期
    III期
    开始
    2024-03
    登记号
    NCT06239727

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙

  11. 正在招募
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    分期
    III期
    开始
    2022-04
    登记号
    NCT05340491

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

  12. 正在招募
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    分期
    III期
    开始
    2020-03
    登记号
    NCT03907826

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗技术副作用与生活质量影像与人工智能
论文中的科室鼻咽癌专科放疗科
牵头的论文14
  1. Effects of Nutritional Interventions on Quality of Life in Patients with Nasopharyngeal Carcinoma Undergoing Radiation Therapy Based on Dynamic Nutritional Risk Screening and Assessment: An Open-Label Single-Center Randomized Phase 3 Trial.2026International journal of radiation oncology, biology, physicsRCT
  2. Improving Radiotherapy Plan Quality for Nasopharyngeal Carcinoma With Enhanced UNet Dose Prediction.2025Cancer medicine免费全文
  3. Deep learning-based quantification of tumor-infiltrating lymphocytes as a prognostic indicator in nasopharyngeal carcinoma: multicohort findings.2025ESMO open免费全文
  4. Infiltrating B-cell subtypes and associated hub genes in nasopharyngeal carcinoma identified from integrated single-cell, bulk RNA-sequencing, and immunohistochemical data.2025Hereditas免费全文
  5. Bacterial Decolonization With Mupirocin Ointment for Acute Radiation Oral Mucositis Prevention: A Phase 3 Randomized Clinical Trial.2025JAMA oncologyRCT免费全文
  6. Development and validation of a machine learning-based model for predicting radiation-induced hypothyroidism in nasopharyngeal carcinoma.2025Radiation oncology (London, England)免费全文
  7. Reducing radiation-induced hypothyroidism by modified delineation of cervical lymphatic drainage area for nasopharyngeal carcinoma treated by intensity-modulated radiation Therapy: 3 years' experience.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  8. HMMR mediates progression of nasopharyngeal carcinoma by inhibiting FAM83D ubiquitination and activating beta-catenin signaling pathway.2025Scientific reports免费全文
  9. The role and molecular mechanism of NOP16 in the pathogenesis of nasopharyngeal carcinoma.2024Cell biochemistry and function
  10. Nutritional Status and Incidence of Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy.2024Nutrition and cancer
  11. Impaired geriatric 8 score is associated with worse survival after radical intensity modulated radiation therapy in elderly patients with nasopharyngeal carcinoma.2023Acta oto-laryngologica
  12. Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma.2023Cancer medicine免费全文
  13. Serum and urine metabolomics analyses reveal metabolic pathways and biomarkers in relation to nasopharyngeal carcinoma.2023Rapid communications in mass spectrometry : RCM
  14. Institutionally validated nomogram predicting prognosis for older patients with nonmetastatic nasopharyngeal carcinoma.2022Future oncology (London, England)
它在 ClinicalTrials.gov 上的全部试验(任何状态)27
  1. Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:正在招募NCT07559877牵头方III期2026-04 启动
  2. Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma正在招募NCT07085988牵头方II期2025-01 启动
  3. Prognostic Value of TIL in Nasopharyngeal Carcinoma邀请入组NCT06763640牵头方2025-01 启动
  4. Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC正在招募NCT06752239牵头方III期2025-01 启动
  5. Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)正在招募NCT07277764牵头方II期2025-10 启动
  6. The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC正在招募NCT06182657牵头方2024-01 启动
  7. Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma正在招募NCT06277050牵头方III期2024-03 启动
  8. Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma进行中,不再招募NCT06762470牵头方2025-01 启动
  9. Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma进行中,不再招募NCT06770699牵头方2025-01 启动
  10. Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma状态不明NCT06259721牵头方II期2024-02 启动
  11. Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis状态不明NCT05893810牵头方III期2023-07 启动
  12. Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma状态不明NCT05177237牵头方II期2021-07 启动
  13. Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma状态不明NCT05128201牵头方II期2021-12 启动
  14. Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC状态不明NCT04557020牵头方III期2020-12 启动
  15. The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma状态不明NCT06268600牵头方不分期2019-01 启动
  16. Effect of Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules on Oral Mucositis in Nasopharyngeal Carcinoma Patients Receiving Radiotherapy.状态不明NCT03112837牵头方不分期2017-03 启动
  17. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.正在招募NCT07258979研究中心I/II期2025-11 启动
  18. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  19. IC Plus Low-dose Radiation Plus Cadonilimab in LANPC正在招募NCT05941741研究中心III期2024-01 启动
  20. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial正在招募NCT05340491研究中心III期2022-04 启动
  21. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients正在招募NCT03907826研究中心III期2020-03 启动
  22. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT05126719研究中心II期2023-04 启动
  23. Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma进行中,不再招募NCT05780372研究中心III期2023-08 启动
  24. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  25. Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma已完成NCT04823468研究中心不分期2021-07 启动
  26. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  27. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma状态不明NCT02944708研究中心III期2015-10 启动
PubMed 以外找到的论文(未计入)34
  1. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncology论文
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  3. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.2025Journal of Clinical Oncology论文
  4. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncology论文
  5. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncology会议摘要
  6. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncology会议摘要
  7. Validation and Development of a Refined M1 Category for Nasopharyngeal Carcinoma Based on the Ninth-Version of AJCC/UICC TNM Staging System in the Immunotherapy Era: A Multicenter Cohort Study2025International Journal of Radiation Oncology*Biology*Physics论文
  8. 847O Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial2024Annals of Oncology论文
  9. Advancing Precise Diagnosis of Nasopharyngeal Carcinoma Through Endoscopy-Based Radiomics Analysis: Transitioning from Static Imaging to Video Analysis2024SSRN Electronic Journal预印本
  10. Advancing Precise Diagnosis of Nasopharyngeal Carcinoma Through Endoscopy-Based Radiomics Analysis: Transitioning from Static Imaging to Video Analysis2024SSRN Electronic Journal预印本
  11. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncology会议摘要
  12. Development of the Ninth Version of the Nasopharyngeal Cancer TNM Staging System by the American Joint Committee on Cancer and Union for International Cancer Control (AJCC/UICC): Recommendations Based on a Multicenter Validation Study and C2024SSRN Electronic Journal预印本
  13. Effect of tumor-immune microenvironment (TIME) on disparate ascending (A) and descending (D) subtypes of nasopharyngeal carcinoma (NPC).2024Journal of Clinical Oncology会议摘要
  14. Endoscopy-Based Radiomics Analysis for Precise Diagnosis of Nasopharyngeal Carcinoma: From Static Images to Video Analysis2024SSRN Electronic Journal预印本
  15. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncology会议摘要
  16. Infiltrating B-cell subtypes and associated hub genes in nasopharyngeal carcinoma identified from integrated single-cell and bulk-RNA sequencing data.2024Journal of Clinical Oncology会议摘要
  17. Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.2024Journal of Clinical Oncology会议摘要
  18. The Global Research of Artificial Intelligence on Nasopharyngeal Carcinoma: A Visualization and Bibliometric Analysis2024SSRN Electronic Journal预印本
  19. The prognostic value of deep learning-based percentage of tumour-infiltrating lymphocytes in nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  20. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  21. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncology会议摘要
  22. Impaired geriatric 8 score is associated with worse survival after radical intensity modulated radiation therapy in elderly patients with nasopharyngeal carcinoma2023Figshare数据集
  23. Intensity modulated radiation therapy in elderly patients with nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  24. Refining the TNM M1 Subcategory for De Novo Metastatic Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physics论文
  25. Sparing concurrent chemotherapy in low-risk locoregionally advanced nasopharyngeal carcinoma: A retrospective study from real-world experience2023Research Square预印本
  26. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Research会议摘要
  27. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figshare数据集
  28. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncology论文
  29. Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.2021Journal of Clinical Oncology会议摘要
  30. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncology会议摘要
  31. Evaluating the Rationality of the International Guideline's Recommendations Regarding Selective Coverage of Level Ib in Node Clinical Target Volume With Nasopharyngeal Carcinoma: Results From a Real-World Series2021International Journal of Radiation Oncology*Biology*Physics论文
  32. Identifying the Optimal Candidates for the Best Utilization of Locoregional Radiation Therapy in Patients With De Novo Metastatic Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physics论文
  33. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncology会议摘要
  34. Retracted: Inhibition of Nasopharyngeal Carcinoma by Beta-Lapachone Occurs by Targeting the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Pathway, Reactive Oxygen Species (ROS) Production, and Autophagy Induction2021Medical Science Monitor论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.07%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

南昌有 3 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
    分期
    II期
    开始
    2022-06
    登记号
    NCT05252078

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江西省肿瘤医院南昌

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗免疫治疗分子标志物与基因
论文中的科室肿瘤内科
牵头的论文2
  1. From tumor microenvironment to emerging biomarkers: the reshaping of the esophageal squamous cell carcinoma tumor microenvironment by neoadjuvant chemotherapy combined with immunotherapy.2024Frontiers in immunology免费全文
  2. microRNA-377 acts as a suppressor in esophageal squamous cell carcinoma through CBX3-dependent P53/P21 pathway.2021Journal of cellular physiology
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients正在招募NCT05252078牵头方II期2022-06 启动
  2. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
  3. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  4. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)已完成NCT04210115研究中心III期2020-02 启动
  5. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
PubMed 以外找到的论文(未计入)7
  1. Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II clinical trial (ALTER-E005).2025Journal of Clinical Oncology会议摘要
  2. Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).2024Journal of Clinical Oncology会议摘要
  3. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  4. A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).2023Journal of Clinical Oncology会议摘要
  5. Comparison of efficacy and safety of neoadjuvant regimens for resectable esophageal squamous cell carcinoma: A meta-analysis.2023Journal of Clinical Oncology会议摘要
  6. A study of neoadjuvant sintilimab combined with chemotherapy TP for locally advanced esophageal squamous cell carcinoma (ESCC).2022Journal of Clinical Oncology会议摘要
  7. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.05%。

牵头论文
8
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 3320242025: 442025

南昌有 3 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    分期
    I/II期
    开始
    2026-05
    登记号
    NCT07547553

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、沈阳、福州、蚌埠、长春

  2. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  3. 正在招募
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-11
    登记号
    NCT07209813

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南京、南昌、杭州、郑州、长沙

  4. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  5. 正在招募
    Phase 2 Study of WGI-0301 for Advanced HCC
    分期
    II期
    开始
    2024-07
    登记号
    NCT06309485

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心南昌、哈尔滨、成都、杭州、武汉、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物影像、人工智能与早期发现复发与预后
论文中的科室放疗科普外/肝胆胰外科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Hepatocellular carcinoma patients with undetectable baseline hepatitis B viral DNA may benefit from immunotherapy.2025BMC gastroenterology免费全文
  2. LDHA-mediated YAP lactylation promotes the tumor progression of hepatocellular carcinoma by inducing YAP dephosphorylation and activation.2025Biology direct免费全文
  3. Ginkgo biloba extract suppresses hepatocellular carcinoma progression by inhibiting the recruitment of myeloid-derived suppressor cells through reduced CXCL1 secretion via SRC downregulation.2025Frontiers in immunology免费全文
  4. Targeting MED8 enhances sorafenib sensitivity in hepatocellular carcinoma by disrupting epithelial-mesenchymal transition mechanisms.2025Journal of enzyme inhibition and medicinal chemistry免费全文
  5. CT radiomics based on different machine learning models for classifying gross tumor volume and normal liver tissue in hepatocellular carcinoma.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  6. Bulk- and single cell-RNA sequencing reveal KIF20A as a key driver of hepatocellular carcinoma progression and immune evasion.2024Frontiers in immunology免费全文
  7. Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis.2024Frontiers in immunology免费全文
  8. Hepatic artery intervention combined with immune-targeted therapy is superior to sequential therapy in BCLC-C hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety已完成NCT06991907牵头方不分期2020-01 启动
  2. Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection进行中,不再招募NCT06934070牵头方(推断)2025-04 启动
  3. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC正在招募NCT07547553研究中心I/II期2026-05 启动
  4. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07209813研究中心II期2025-11 启动
  5. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  6. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  7. Phase 2 Study of WGI-0301 for Advanced HCC正在招募NCT06309485研究中心II期2024-07 启动
  8. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.04%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 0020232024: 1120242025: 002025

南昌有 3 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
    分期
    III期
    开始
    2019-01
    登记号
    NCT03941561

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心南昌、合肥、芜湖

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期
论文中的科室肿瘤内科放疗科
牵头的论文4
  1. Identification and characterization of ferroptosis-related genes in therapy-resistant gastric cancer.2024Medicine免费全文
  2. Resveratrol inhibits TGF-β1-induced EMT in gastric cancer cells through Hippo-YAP signaling pathway.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  3. HEIH Promotes Malignant Progression of Gastric Cancer by Regulating STAT3-Mediated Autophagy and Glycolysis.2022Disease markers免费全文
  4. MiR-1299 functions as a tumor suppressor to inhibit the proliferation and metastasis of gastric cancer by targeting ARF6.2022Genes & genomics
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  2. S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)正在招募NCT03941561研究中心III期2019-01 启动
  3. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  4. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  5. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  6. Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor状态不明NCT03399253研究中心II/III期2017-12 启动
  7. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)已完成NCT02745509研究中心不分期2016-03 启动
  8. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  9. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南昌有 10 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025

南昌有 10 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

江西省肿瘤医院

Jiangxi Cancer Hospital

南昌

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Jiangxi Cancer Hospital of Nanchang University; Jiangxi Provincial Cancer Hospital; Jiangxi cancer Hospital; Jiangxi Cancer Hospital); Jiangxi Cancer Hospital Nanchang; Jiangxi Cancer Hospital & Institute; Jiangxi Cancer Hospital (Jiangxi Second People's Hospital); Jiangxi Cancer Hospital of Nanchang Medical College

提出更正下载数据